Pioglitazonum [Inn-Latin] en es it fr

Pioglitazonum [Inn-Latin] Brand names, Pioglitazonum [Inn-Latin] Analogs

Pioglitazonum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Pioglitazonum [Inn-Latin] Chemical_Formula


Pioglitazonum [Inn-Latin] RX_link


Pioglitazonum [Inn-Latin] fda sheet

Pioglitazonum_[Inn-Latin] FDA

Pioglitazonum [Inn-Latin] msds (material safety sheet)

Pioglitazonum_[Inn-Latin] MSDS

Pioglitazonum [Inn-Latin] Synthesis Reference

K. Meguro, T. Fujita, U.S. Pat. 4,687,777 (1987)

Pioglitazonum [Inn-Latin] Molecular Weight

356.44 g/mol

Pioglitazonum [Inn-Latin] Melting Point


Pioglitazonum [Inn-Latin] H2O Solubility


Pioglitazonum [Inn-Latin] State


Pioglitazonum [Inn-Latin] LogP

No information avaliable

Pioglitazonum [Inn-Latin] Dosage Forms

Oral tablets

Pioglitazonum [Inn-Latin] Indication

Treatment of Type II diabetes mellitus

Pioglitazonum [Inn-Latin] Pharmacology

Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent.

Pioglitazonum [Inn-Latin] Absorption

Following oral administration, in the fasting state, pioglitazone is first measurable in serum within 30 minutes, with peak concentrations observed within 2 hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does not alter the extent of absorption.

Pioglitazonum [Inn-Latin] side effects and Toxicity

Hypogycemia; LD50=mg/kg (orally in rat)

Pioglitazonum [Inn-Latin] Patient Information

Pioglitazonum [Inn-Latin] Organisms Affected

Humans and other mammals